Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

<p>Pharmacokinetic profile for EnaV in dose-escalation phase. Plasma/serum concentrations of (A) conjugated EnaV and (B) MMAE at 3Q4W. Dots indicate observed data; lines indicate mean data. EnaV, enapotamab vedotin; LLOQ, lower limit of quantitation; MMAE, monomethyl auristatin E</p>

Αποθηκεύτηκε σε:

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Kristoffer Staal Rohrberg (15009138) (author)
Άλλοι συγγραφείς:	Juanita S. Lopez (22687839) (author), Mohammed M. Milhem (15352499) (author), Christian U. Blank (14850778) (author), Irene Reijers (22687842) (author), Fiona Thistlethwaite (22687845) (author), Ruth Plummer (15028641) (author), Sarina A. Piha-Paul (15294428) (author), Pasi A. Jänne (14954872) (author), Elaine Shum (14955138) (author), Heather M. Shaw (22687848) (author), Philip R. Debruyne (20432881) (author), Cristopher Lao (22687851) (author), Jean-Francois Baurain (15031089) (author), Jennifer H. Choe (15052775) (author), Eelke Gort (17740951) (author), Yujie Zhao (22687854) (author), Guy Jerusalem (15017648) (author), Patrick Schöffski (15013461) (author), Andrew William Chen (22687857) (author), Eric A. Cohen (15017996) (author), Walter C. Mankowski (22687860) (author), Leonid Roshkovan (22687863) (author), Sharyn I. Katz (22687866) (author), Despina Kontos (15018005) (author), Lauren K. Brady (22687869) (author), Mohammed Qutaish (22687872) (author), Patricia Garrido Castro (22687875) (author), Nora Pencheva (22687878) (author), Gaurav Bajaj (22687881) (author), Yali Fu (22687884) (author), Kristian Windfeld (22687887) (author), Panagiota Reiter (22687890) (author), Maria Jure-Kunkel (15117740) (author), Brandon W. Higgs (15035279) (author), Katayoun I. Amiri (22687893) (author), Tahamtan Ahmadi (22687896) (author), Ulf Forssmann (22687899) (author), Suresh S. Ramalingam (14951413) (author), Ignace Vergote (15027870) (author)
Έκδοση:	2025
Θέματα:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
Ετικέτες:	Προσθήκη ετικέτας Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

_version_	1849927621949784064
author	Kristoffer Staal Rohrberg (15009138)
author2	Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
author2_role	author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author
author_facet	Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
author_role	author
dc.creator.none.fl_str_mv	Kristoffer Staal Rohrberg (15009138) Juanita S. Lopez (22687839) Mohammed M. Milhem (15352499) Christian U. Blank (14850778) Irene Reijers (22687842) Fiona Thistlethwaite (22687845) Ruth Plummer (15028641) Sarina A. Piha-Paul (15294428) Pasi A. Jänne (14954872) Elaine Shum (14955138) Heather M. Shaw (22687848) Philip R. Debruyne (20432881) Cristopher Lao (22687851) Jean-Francois Baurain (15031089) Jennifer H. Choe (15052775) Eelke Gort (17740951) Yujie Zhao (22687854) Guy Jerusalem (15017648) Patrick Schöffski (15013461) Andrew William Chen (22687857) Eric A. Cohen (15017996) Walter C. Mankowski (22687860) Leonid Roshkovan (22687863) Sharyn I. Katz (22687866) Despina Kontos (15018005) Lauren K. Brady (22687869) Mohammed Qutaish (22687872) Patricia Garrido Castro (22687875) Nora Pencheva (22687878) Gaurav Bajaj (22687881) Yali Fu (22687884) Kristian Windfeld (22687887) Panagiota Reiter (22687890) Maria Jure-Kunkel (15117740) Brandon W. Higgs (15035279) Katayoun I. Amiri (22687893) Tahamtan Ahmadi (22687896) Ulf Forssmann (22687899) Suresh S. Ramalingam (14951413) Ignace Vergote (15027870)
dc.date.none.fl_str_mv	2025-11-26T07:40:26Z
dc.identifier.none.fl_str_mv	10.1158/2767-9764.30719277
dc.relation.none.fl_str_mv	https://figshare.com/articles/figure/Figure_S3_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719277
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
dc.title.none.fl_str_mv	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
dc.type.none.fl_str_mv	Image Figure info:eu-repo/semantics/publishedVersion image
description	<p>Pharmacokinetic profile for EnaV in dose-escalation phase. Plasma/serum concentrations of (A) conjugated EnaV and (B) MMAE at 3Q4W. Dots indicate observed data; lines indicate mean data. EnaV, enapotamab vedotin; LLOQ, lower limit of quantitation; MMAE, monomethyl auristatin E</p>
eu_rights_str_mv	openAccess
id	Manara_e8e6dd9440a46fd5cba1bf20350fe67d
identifier_str_mv	10.1158/2767-9764.30719277
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30719277
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid TumorsKristoffer Staal Rohrberg (15009138)Juanita S. Lopez (22687839)Mohammed M. Milhem (15352499)Christian U. Blank (14850778)Irene Reijers (22687842)Fiona Thistlethwaite (22687845)Ruth Plummer (15028641)Sarina A. Piha-Paul (15294428)Pasi A. Jänne (14954872)Elaine Shum (14955138)Heather M. Shaw (22687848)Philip R. Debruyne (20432881)Cristopher Lao (22687851)Jean-Francois Baurain (15031089)Jennifer H. Choe (15052775)Eelke Gort (17740951)Yujie Zhao (22687854)Guy Jerusalem (15017648)Patrick Schöffski (15013461)Andrew William Chen (22687857)Eric A. Cohen (15017996)Walter C. Mankowski (22687860)Leonid Roshkovan (22687863)Sharyn I. Katz (22687866)Despina Kontos (15018005)Lauren K. Brady (22687869)Mohammed Qutaish (22687872)Patricia Garrido Castro (22687875)Nora Pencheva (22687878)Gaurav Bajaj (22687881)Yali Fu (22687884)Kristian Windfeld (22687887)Panagiota Reiter (22687890)Maria Jure-Kunkel (15117740)Brandon W. Higgs (15035279)Katayoun I. Amiri (22687893)Tahamtan Ahmadi (22687896)Ulf Forssmann (22687899)Suresh S. Ramalingam (14951413)Ignace Vergote (15027870)CancerImmuno-oncologyClinical Research and TrialsClinical Trial ResultsImmunologyAntibodies/immunoconjugatesLung CancerMelanomaOvarian CancerSarcomas<p>Pharmacokinetic profile for EnaV in dose-escalation phase. Plasma/serum concentrations of (A) conjugated EnaV and (B) MMAE at 3Q4W. Dots indicate observed data; lines indicate mean data. EnaV, enapotamab vedotin; LLOQ, lower limit of quantitation; MMAE, monomethyl auristatin E</p>2025-11-26T07:40:26ZImageFigureinfo:eu-repo/semantics/publishedVersionimage10.1158/2767-9764.30719277https://figshare.com/articles/figure/Figure_S3_from_Phase_I_II_Study_of_AXL-Specific_Antibody_Drug_Conjugate_Enapotamab_Vedotin_in_Patients_with_Advanced_Solid_Tumors/30719277CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307192772025-11-26T07:40:26Z
spellingShingle	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors Kristoffer Staal Rohrberg (15009138) Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas
status_str	publishedVersion
title	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_full	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_fullStr	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_full_unstemmed	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_short	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
title_sort	Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors
topic	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunology Antibodies/immunoconjugates Lung Cancer Melanoma Ovarian Cancer Sarcomas

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

Παρόμοια τεκμήρια